Posts by: Timea Polgar

Timea Polgar

Timea is a Molecular biologist (MSc) & Computational chemist (MSc, PhD), science liaison, and strategic business development and marketing specialist, with 15 years in pharmaceutical R&D, biotech and scientific software development.

May 31, 2016May 31, 2016

Antiepileptic Drug Fycompa, Already Approved in US, Launched in Japan

News

Eisai recently announced the company will launch its novel antiepileptic drug (AED) Fycompa, which is intended as an adjunctive therapy for people suffering from epilepsy and experiencing partial-onset or primary generalized tonic-clonic seizures ... Read more

May 18, 2016

Bial’s Submission for Once-daily Epilepsy Treatment Zebinix Accepted by EMA

News

Bial has announced that the European Medicines Agency (EMA) will review recent clinical trial data for Zebinix (eslicarbazepine acetate) as a once-daily treatment for patients suffering from newly diagnosed epilepsy. The results of ... Read more